2026-02-12, 7:19:28 p.m.
REDWOOD CITY, Calif. — February 13, 2026 — Leads & Copy — Coherus Oncology, Inc. (NASDAQ: CHRS) has announced the pricing of its underwritten public offering of 28,600,000 shares of common stock. The shares are priced at $1.75 per share, before underwriting discounts and commissions. All shares in the offering are being sold by the company. Gross proceeds to Coherus are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses.
Underwriters have been granted a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 17, 2026, pending customary closing conditions.
Coherus intends to use the net proceeds from the offering to support ongoing commercialization of LOQTORZI® (toripalimab-tpzi), continue clinical development of its product candidates, and for working capital and other general corporate purposes.
TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as the joint bookrunners for the offering.
The securities are being offered by Coherus pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291520) previously filed with the SEC on November 13, 2025. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus may be obtained from TD Securities (USA) LLC, Guggenheim Securities, LLC, or Oppenheimer & Co. Inc.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Coherus Oncology is a commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates. The company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with pipeline candidates and partners.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
Source: Coherus Oncology
